Detalhe da pesquisa
1.
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Ann Neurol
; 89(6): 1088-1098, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33586143
2.
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
Mult Scler
; 28(3): 480-486, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34498507
3.
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
Mult Scler
; 23(1): 94-105, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27003945
4.
COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
Br J Clin Pharmacol
; 82(2): 380-8, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27060836
5.
Quantitative evaluation of all hexamers as exonic splicing elements.
Genome Res
; 21(8): 1360-74, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21659425
6.
Melanoma risk loci as determinants of melanoma recurrence and survival.
J Transl Med
; 11: 279, 2013 Nov 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-24188633
7.
Partially Linear Single Index Cox Regression Model in Nested Case-Control Studies.
Comput Stat Data Anal
; 67: 199-212, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26806991
8.
A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder.
Front Neurol
; 14: 1099376, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37114235
9.
Serum microRNAs as biomarkers for recurrence in melanoma.
J Transl Med
; 10: 155, 2012 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-22857597
10.
Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.
Mult Scler Relat Disord
; 50: 102849, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676197
11.
Peginterferon ß-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis.
Ther Adv Neurol Disord
; 11: 1756286418795085, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181780
12.
Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.
Mult Scler Relat Disord
; 22: 134-138, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29679749
13.
Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN.
Ther Adv Neurol Disord
; 11: 1756286418791143, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181778
14.
Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.
J Neurol
; 263(9): 1778-87, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27314959
15.
A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.
Clin Cancer Res
; 21(21): 4903-12, 2015 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26089374
16.
Application of the asthma phenotype algorithm from the Severe Asthma Research Program to an urban population.
PLoS One
; 7(9): e44540, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23028556
17.
The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.
PLoS One
; 6(9): e25264, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21980408
18.
miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.
Cancer Cell
; 20(1): 104-18, 2011 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-21741600
19.
Outcomes of the RESTOR-MV Trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve).
J Am Coll Cardiol
; 56(24): 1984-93, 2010 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-21126639